NuVasive receives FDA approval for two-level cervical disc replacement
Click Here to Manage Email Alerts
NuVasive Inc. has announced FDA approval of the Simplify cervical artificial disc for two-level cervical total disc replacement, according to the release.
An addition to NuVasive’s C360 portfolio of spinal surgery technology, the Simplify disc achieved an overall success rate nearly 10% higher compared with anterior cervical discectomy and fusion, according to the release.
“This approval is an incredible achievement for the Simplify disc and further broadens the growth opportunities for the NuVasive C360 portfolio,” Massimo Calafiore, executive vice president of global business units at NuVasive, said in the release. “There is immense surgeon excitement for this latest edition to our cervical offering, and the expanded two-level indication provides greater opportunities to bring the most clinically effective technology in the [cervical total disc replacement] cTDR market to more patients,” Calafiore added.
Read more about
Click Here to Manage Email Alerts